Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at…
Pharmaceuticals, Biotechnology and Life Sciences
Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at…
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage…
CARSON CITY, Nev., March 06, 2024 (GLOBE NEWSWIRE) — BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company…
TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical…
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization…
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO)…
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational…
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and…
Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies…
CBX-250 is a first-in-class, potent, and specific T-cell engager for the treatment of myeloid leukemia Abstract summarizing preclinical characteristics of…